West China Journal of Stomatology ›› 2019, Vol. 37 ›› Issue (2): 214-219.doi: 10.7518/hxkq.2019.02.015

Previous Articles     Next Articles

Treatment plan and prognosis of salivary adenoid cystic carcinoma with lung metastasis

Wen Su1,2,Hongyu Yang1,2()   

  1. 1.Dept. of Stomatology, Anhui Medical University, Hefei 230032, China
    2.Dept. of Oral and Maxillofacial Surgery, Shenzhen Hospital, Peking University, Shenzhen 518036, China
  • Received:2018-07-30 Revised:2018-10-20 Online:2019-04-01 Published:2019-04-28
  • Contact: Hongyu Yang E-mail:hyyang192@hotmail.com
  • Supported by:
    The National Natural Science Foundation of China(81572654);The Basic Research Program of Shenzhen Innovation Council(JCYJ20150403091443303);The Basic Research Program of Shenzhen Innovation Council(JCYJ20150403091443286);The Basic Research Program of Shenzhen Innovation Council(JCYJ2016042873933559);The Basic Research Program of Shenzhen Innovation Council(SZBC2017023);Sanming Project of Medicine in Shenzhen(SZSM201512036)

Abstract:

Salivary adenoid cystic carcinoma (SACC) is a common malignant tumor in the oral and maxillofacial region and accounts for approximately 3%-5% of all head and neck carcinomas. SACC always occurs in the palatal salivary gland and parotid gland. The tumor has the characteristics of strong invasion, perineural invasion, high hematogenous metastasis, and low lymph node metastasis rate. The biological characteristics of SACC determine the specificity of clinical treatment. Thus far, few clinical trials have investigated the efficacy of systemic therapy owing to the rarity of SACC with lung metastasis. Moreover, long-term results are poor, and no consensus on standard treatment has been reached yet. This systematic review aims to provide a retrospective analysis of treatment options and prognosis for SACC with lung metastasis and evidence for future clinical treatment.

Key words: salivary adenoid cystic carcinoma, lung metastatic, clinical treatment

CLC Number: